Skip to main content
PMC home page
Cellular & Molecular Biology Letters logoLink to Cellular & Molecular Biology Letters
. 2010 May 24;15(3):440–450. doi: 10.2478/s11658-010-0016-2

Celecoxib increases retinoid sensitivity in human colon cancer cell lines

Jian-Pei Liu 1, Hong-Bo Wei 1,✉, Zong-Heng Zheng 1, Wei-Ping Guo 1, Jia-Feng Fang 1
PMCID: PMC6275995  PMID: 20496179

Abstract

Retinoid resistance has limited the clinical application of retinoids as differentiation-inducing and apoptosis-inducing drugs. This study was designed to investigate whether celecoxib, a selective COX-2 inhibitor, has effects on retinoid sensitivity in human colon cancer cell lines, and to determine the possible mechanism of said effects. Cell viability was measured using the MTT assay. Apoptosis was detected via Annexin-V/PI staining and the flow cytometry assay. PGE2 production was measured with the ELISA assay. The expression of RARβ was assayed via western blotting. The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Further study showed the ATRA and celecoxib combination induced greater apoptosis, but that the addition of PGE2 did not affect the enhanced growth-inhibitory and apoptosis-inducing effects of the combination. Moreover, NS398 (another selective COX-2 inhibitor) did not affect the inhibitory effects of ATRA in the two cell lines. Western blotting showed that the expression of RARβ in HT-29 cell lines was increased by celecoxib, but not by NS398, and that the addition of PGE2 did not affect the celecoxib-induced expression of the retinoic acid receptor beta. In conclusion, celecoxib increased the expression of RARβ and the level of cellular ATRA sensitivity through COX-2-independent mechanisms. This finding may provide a potential strategy for combination therapy.

Key words: Colonic neoplasm, Retinoic acid, Celecoxib, Sensitivity

Full Text

The Full Text of this article is available as a PDF (2.5 MB).

Abbreviations used

ATRA

all-trans retinoic acid

COX-2

Cycloxygenase-2

4HPR

N-(4-hydroxyphenyl) retinamide

MTT

methyl thiazolyl tetrazolium

PGE2

prostaglandin E2

RARβ

retinoic acid receptor beta

References

  • 1.Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet. 2005;365:153–165. doi: 10.1016/S0140-6736(05)17706-X. [DOI] [PubMed] [Google Scholar]
  • 2.Sabharwal A., Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev. Anticancer Ther. 2007;7:477–487. doi: 10.1586/14737140.7.4.477. [DOI] [PubMed] [Google Scholar]
  • 3.Gudas L.J., Sporn M.B., Roberts A.B. Cellular biology and biochemistry of the retinoids. In: Sporn M.B., Roberts A.B., Goodman D.S., editors. The retinoids: Biology, Chemistry, and Medicine. 2nd edition. New York: Raven Press; 1994. pp. 443–520. [Google Scholar]
  • 4.Xu X.C. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 2007;253:14–24. doi: 10.1016/j.canlet.2006.11.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lee M.O., Han S.Y., Jiang S., Park J.H., Kim S.J. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem. Pharmacol. 2000;59:485–496. doi: 10.1016/S0006-2952(99)00355-X. [DOI] [PubMed] [Google Scholar]
  • 6.van Zandwijk N., Dalesio O., Pastorino U., de Vries N., van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 2000;92:977–986. doi: 10.1093/jnci/92.12.977. [DOI] [PubMed] [Google Scholar]
  • 7.Khuri F.R., Lee J.J., Lippman S.M., Kim E.S., Cooper J.S., Benner S.E., Winn R., Pajak T.F., Williams B., Shenouda G., Hodson I., Fu K., Shin D.M., Vokes E.E., Feng L., Goepfert H., Hong W.K. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst. 2006;98:441–450. doi: 10.1093/jnci/djj091. [DOI] [PubMed] [Google Scholar]
  • 8.Koki A.T., Leahy K.M., Masferrer J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs. 1999;8:1623–1638. doi: 10.1517/13543784.8.10.1623. [DOI] [PubMed] [Google Scholar]
  • 9.Rostom A., Dube C., Lewin G., Tsertsvadze A., Barrowman N., Code C., Sampson M., Moher D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2007;146:376–389. doi: 10.7326/0003-4819-146-5-200703060-00010. [DOI] [PubMed] [Google Scholar]
  • 10.Simeone A.M., Li Y.J., Broemeling L.D., Johnson M.M., Tuna M., Tari A.M. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res. 2004;64:1224–1228. doi: 10.1158/0008-5472.CAN-03-2188. [DOI] [PubMed] [Google Scholar]
  • 11.Tari A.M., Simeone A.M., Li Y.J., Gutierrez-Puente Y., Lai S., Symmans W.F. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab. Invest. 2005;85:1357–1367. doi: 10.1038/labinvest.3700339. [DOI] [PubMed] [Google Scholar]
  • 12.Schroeder C.P., Kadara H., Lotan D., Woo J.K., Lee H.Y., Hong W.K., Lotan R. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res. 2006;66:9762–9770. doi: 10.1158/0008-5472.CAN-05-4124. [DOI] [PubMed] [Google Scholar]
  • 13.Li M., Song S., Lippman S.M., Zhang X.K., Liu X., Lotan R., Xu X.C. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene. 2002;21:411–418. doi: 10.1038/sj.onc.1205106. [DOI] [PubMed] [Google Scholar]
  • 14.Song S., Lippman S.M., Zou Y., Ye X., Ajani J.A., Xu X.C. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene. 2005;24:8268–8276. doi: 10.1038/sj.onc.1208992. [DOI] [PubMed] [Google Scholar]
  • 15.Delage B., Bairras C., Buaud B., Pallet V., Cassand P. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. Int. J. Cancer. 2005;116:839–846. doi: 10.1002/ijc.21108. [DOI] [PubMed] [Google Scholar]
  • 16.Mernitz H., Smith D.E., Zhu A.X., Wang X.D. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett. 2006;244:101–108. doi: 10.1016/j.canlet.2005.12.001. [DOI] [PubMed] [Google Scholar]
  • 17.Freemantle S.J., Spinella M.J., Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22:7305–7315. doi: 10.1038/sj.onc.1206936. [DOI] [PubMed] [Google Scholar]
  • 18.Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 2002;531:278–284. doi: 10.1016/S0014-5793(02)03535-4. [DOI] [PubMed] [Google Scholar]
  • 19.Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000;60:6045–6051. [PubMed] [Google Scholar]
  • 20.Niederberger E., Tegeder I., Vetter G., Schmidtko A., Schmidt H., Euchenhofer C., Brautigam L., Grosch S., Geisslinger G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NFkappaB. FASEB J. 2001;15:1622–1624. doi: 10.1096/fj.00-0716fje. [DOI] [PubMed] [Google Scholar]
  • 21.Zrieki A., Farinotti R., Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 2008;25:1991–2001. doi: 10.1007/s11095-008-9596-1. [DOI] [PubMed] [Google Scholar]
  • 22.Sulova Z., Macejova D., Seres M., Sedlak J., Brtko J., Breier A. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol. In Vitro. 2008;22:96–105. doi: 10.1016/j.tiv.2007.08.011. [DOI] [PubMed] [Google Scholar]
  • 23.Soprano D.R., Qin P., Soprano K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 2004;24:201–221. doi: 10.1146/annurev.nutr.24.012003.132407. [DOI] [PubMed] [Google Scholar]
  • 24.Grosch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 2006;98:736–747. doi: 10.1093/jnci/djj206. [DOI] [PubMed] [Google Scholar]
  • 25.Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 2004;67:1469–1478. doi: 10.1016/j.bcp.2003.12.014. [DOI] [PubMed] [Google Scholar]
  • 26.Lefebvre B., Brand C., Flajollet S., Lefebvre P. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol. Endocrinol. 2006;20:2109–2121. doi: 10.1210/me.2005-0321. [DOI] [PubMed] [Google Scholar]

Articles from Cellular & Molecular Biology Letters are provided here courtesy of BMC

RESOURCES